CALR mutations occur in about 20% of patients with primary and post-essential thrombocythemia myelofibrosis, as per the study ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

The small pharma has inched closer to profitability since launching its first drug at the end of 2011. Called Jakafi, it treats the rare blood cancer myelofibrosis. Financial details regarding the ...

GSK had been expecting approval only for second-line use in patients previously treated with Jakafi or other JAK drugs, like Bristol Myers Squibb's Inrebic (fedratinib) and CTI Biopharma's Vonjo ...

Ruxolitinib is a kinase inhibitor, prescribed for high-risk myelofibrosis. The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Bacillus calmette-guerin ...

Some drugs can shrink your spleen ... Gene mutations: Your doctor may put you on a JAK inhibitor such asruxolitinib (Jakafi). It targets the mutations experts believe cause myelofibrosis.

The company's sales topped estimates for the fourth quarter as its two biggest drugs, Jakafi and Opzelura, grew year-over-year. Despite the strong latest quarter for the two drugs, Incyte's ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Despite the healthy growth, Incyte provided guidance for leading drugs, Jakafi and Opzelura, that were below expectations. Management expects sales of the hematology drug Jakafi to be between $2. ...